Non-small cell lung cancer
Conditions
Interventions
The treatment schedule included carboplatin AUC 4 on day 1, and gemcitabine 1000 mg/ m2 on days 1 and 8, every 3 weeks. (Below six courses more than three courses.)
Sponsors
Institute of Biomedical Research and Innovation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with histologic or cytologic confirmation of locally advanced or metastatic NSCLC 2)Received either no prior chemotherapy were eligible 3)Measurable lesions 4)Age ≥ 70; 5)Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 6)Adequate organ function 7)Life expectancy for more than 3 months 8)Written informed consent
Exclusion criteria
Exclusion criteria: 1)After thoracic irradiation 2)A case having severe infection and a serious complication 3)Requiring treatment pleural/ascites /pericardial effusion, 4)Interstitial pneumonia or active lung fibrosis on chest X-ray, 5)Symptomatic brain metastases 6)Double cancer 7)Others
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response Rate(according to RECIST criteria) | — |
Secondary
| Measure | Time frame |
|---|---|
| Median survival time, 1-year survival, Adverse events, Time to Progression, Quality of Life | — |
Countries
Japan
Contacts
Public ContactTakashi Nishimura
Kobe City General Hospital Respiratory Medicine
Outcome results
None listed